Figure 2From: CA15-3 is a useful serum tumor marker for diagnostic integration of hybrid positron emission tomography with integrated computed tomography during follow-up of breast cancer patients Right side: example of a patient with negative PETCT findings (a: coronal view; b: transaxial view) and CA15-3 levels of 45.3 UI/mL; left side: the same patient 6 months later with positive PETCT findings (c: coronal view; d: transaxial view) as well as CA15-3 levels of 116.8 UI/mL. Arrows indicate the metastatic sites.Back to article page